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Background: The phosphodiesterase inhibitor cilostazol has beneficial effects on atherosclerosis by virtue of
vasodilatory and antiplatelet effects. However, less is known about the effect of cilostazol on arterial stiffness and
biochemical markers related to vascular inflammation and endothelial dysfunction in type 2 diabetic patients with
metabolic syndrome.
Methods: In this randomized, double-blind, crossover trial, 45 diabetic patients with metabolic syndrome were
randomly assigned to either the cilostazol group (50 mg for 2 weeks, 100 mg for 6 weeks) or placebo group for an
8-week treatment phase, and then crossed over. Brachial-ankle pulse wave velocity (baPWV) and serum levels of
inflammatory cytokines and vascular cellular adhesion molecules were measured before and after each treatment
phase.
Results: Compared with the placebo group, the mean baPWV did not improve in the cilostazol group (mean
difference 31.42 cm/sec, 95% CI −55.67 to 118.5). Cilostazol treatment significantly reduced soluble vascular cellular
adhesion molecule-1 (sVCAM-1) level (from 1288.7 ± 285.6 to 1168.2 ± 252.3 ng/dL, P = 0.0003), and there was also
significant mean difference between groups (mean difference 105.18 ng/dL, 95% CI 10.65 to 199.71). However,
other biochemical markers including lipid profiles, high sensitivity C-reactive protein, adiponectin, interleukin-6,
tumor necrosis factor-alpha, monocyte chemotactic protein-1, and soluble intercellular adhesion molecule-1 did not
improve with cilostazol treatment.
Conclusion: Cilostazol treatment significantly reduced serum sVCAM-1 level, but this short term treatment was not
associated with beneficial effect on arterial stiffness and other inflammatory markers.
Trial registration: (Clinical trial reg. no. NCT00573950, clinicaltrials.gov.)
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Cardiovascular disease (CVD) is the major cause of mor-
tality in patients with diabetes and metabolic syndrome.
Chronic inflammation and endothelial dysfunction appear
to be major components contributing to the development
of atherosclerosis in a background of insulin resistance in
diabetic patients [1,2]. Biochemical markers such as
proinflammatory cytokines and vascular cellular adhesion
molecules are related to the progression of atherosclerosis
and CVD [3,4] and are also helpful for the screening of
subclinical atherosclerosis [5,6].
On the other hands, subclinical atherosclerosis and
increased arterial stiffness are early changes predicting
the development of CVD. Various noninvasive measures
of these changes, such as carotid intima-media thickness
(IMT), pulse wave velocity (PWV), and coronary artery
calcification have been developed and commonly used
[7]. Of these methods, PWV is the most commonly used
measure of arterial stiffness, and predicts the develop-
ment of CVD and mortality in type 2 diabetes [8].
Cilostazol is a selective inhibitor of cyclic phospho-
diesterase 3, which is used for the treatment of chronic
peripheral artery disease, by virtue of its antiplatelet and
vasodilatory activities [9]. A growing body of evidence
obtained from animal models suggests that cilostazol has
beneficial effects on lipid metabolism either by cAMP-
mediated increases in lipoprotein lipase, or by inhibiting
the production of cytokines related to the progression of
atherosclerotic lesions [10,11].
Previous clinical studies showed that cilostazol treat-
ment attenuated the progression of carotid IMT in type 2
diabetic patients [12,13]. The favorable effects of cilostazol
on atherosclerosis were also demonstrable in diabetic pa-
tients with known peripheral artery disease (PAD); soluble
CD40 ligand and hs-CRP levels were significantly de-
creased, and arterial compliance was modestly improved
[14,15], However, the effects on arterial stiffness and va-
rious inflammatory markers related to the progression of
atherosclerosis have not been evaluated in subjects with
type 2 diabetes but not having coronary heart disease or
PAD. Therefore, we conducted a randomized, double-
blind, crossover study to clarify the efficacy of cilostazol in
preventing the progression of arterial stiffness using
brachial-ankle PWV (baPWV) in patients with type 2
diabetes and metabolic syndrome. We also evaluated the
effect of cilostazol on proinflammatory cytokines and in-
flammatory markers related to vascular inflammation and
endothelial dysfunction.Materials and methods
Subjects and study design
The eligible participants were patients aged over 18
years with type 2 diabetes and metabolic syndrome.Type 2 diabetes was defined by the American Diabetes
Association criteria [16]. All patients had been treated
with oral hypoglycemic agents or insulin. Metabolic
syndrome was defined according to Adult Treatment
Panel III of the National Cholesterol Education Program
guidelines [17], modified in accordance with the World
Health Organization’s proposed waist circumference
(WC) cut-off points for Asians. Subjects with metabolic
syndrome were required to meet three or more of the fol-
lowing criteria: WC ≥90 cm in men and ≥80 cm in women,
serum triglyceride level ≥150 mg/dL, HDL-cholesterol
(HDL-C) levels <40 mg/dL in men and <50 mg/dL in
women, impaired fasting glucose ≥100 mg/dL or anti-
diabetic treatment, and blood pressure ≥130/85 mmHg or
treatment for hypertension.
Subjects who had taken a stable dose of anti-
hypertensive or lipid-lowering drugs for at least 8 weeks
before the study were enrolled, and these medication
dosages were maintained throughout the study. The
major exclusion criteria included known CVDs including
coronary heart disease and peripheral artery disease;
congestive heart failure; severe hepatic dysfunction and
renal dysfunction; treatment with thiazolidinendione
within 8 weeks at screening; current use of anticoagu-
lants, antiplatelet agents, and corticosteroid supple-
ments; and history of drug or alcohol abuse. All subjects
gave informed consent and the protocol was approved
by the Institutional Review Board of Korea University
Hospital.
Of 49 Korean subjects screened, 4 did not meet the
diagnostic criteria of metabolic syndrome. As a result,
45 Korean patients were randomly assigned to receive
cilostazol (50 mg for the first 2 weeks and 100 mg for
the next 6 weeks) or matching placebo for 8 weeks. The
dose titration was set to minimize adverse events related
to study medications.
With a washout period of 8 weeks, participants were
then crossed over to the other treatment arm for a fur-
ther 8 weeks. Cilostazol and placebo tablets were sup-
plied by Otsuka Pharmaceuticals (Tokyo, Japan). The
tablets were identical in size, color, and taste. All partici-
pants underwent a comprehensive physical examination,
anthropometric measurements, and blood sampling for
biochemical analyses, and baPWV measurements at
baseline and after treatment at each treatment phase.
Blood pressure was measured in a standardized manner
with a mercury sphyngomanometer; two separate mea-
surements were taken after 5 min of rest and the mean
was calculated. Anthropometric measurements were
taken after an overnight fast. Height, body weight, BMI
(kg/m2), and WC of all subjects were recorded. Blood
was drawn for biochemical analysis after an overnight
fast. This clinical trial is registered as NCT00573950 at
clinicaltrials.gov.
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Arterial stiffness was assessed by baPWV, which was
measured using a model BP-203RPE II volume-ple-
thymographic apparatus (Colin, Komaki, Japan). Each
participant was examined in a supine position with elec-
trocardiographic electrodes placed on both wrists and
cuffs wrapped around both brachia and ankles. The
pulse waveforms were recorded using a semiconductor
pressure sensor. Transmission time was calculated as the
time for the waveform to travel between the right arm
and both ankles, and the transmission distance between
the right brachium and ankle was automatically calcu-
lated based on the height of the participant. The baPWV
was automatically calculated by dividing transmission
distance by the transmission time. The means of right
and left baPWV were used for the analysis.
Measurement of biochemical markers
Venous blood samples were drawn from each patient
after overnight fasting. Blood samples were centrifuged
to obtain serum, and the serum was stored at −80°C.
High sensitivity C-reactive protein (hsCRP) levels were
measured using a CRP ELISA kit (Immunodiagno,
Bensheim, Germany); the intra-and interassay coef-
ficients of variation were 6.5% and 10.4%, respectively.
Total cholesterol, triglyceride, HDL-C, and LDL-C levelsFigure 1 Trial design.were determined by enzymatic methods using a model
747 automated clinical chemistry analyzer (Hitachi,
Tokyo, Japan). Homeostasis model assessment of insulin
resistance index was calculated using the the formula
(fasting insulin [μIU/mL] × fasting glucose [mmol/L] /
22.5), and quantitative insulin sensitivity check index
was calculated as 1 / (log fasting insulin [μIU/mL] + log
fasting glucose [mg/dL]).
Serum levels of adiponectin, interleukin-6 (IL-6), soluble
vascular cellular adhesion molecule-1 (sVCAM-1), soluble
intercellular adhesion molecule-1 (sICAM-1), monocyte
chemotactic protein-1 (MCP-1), and tumor necrosis
factor-alpha (TNF-α) were measured using a MILLIPLEX™
Human Cytokine/Chemokine panel (Millipore, Billerica,
MA). Intra- and interassay coefficients of variation were
9.2 and 15.9% for adiponectin, 8.1 and 11.6% for IL-6, 4.5
and 8.5% for sVCAM-1, 7.9 and 9.7% for sICAM-1, 6.1
and 12.0% for MCP-1, and 10.5 and 15.9% for TNF-α,
respectively.
Statistical analysis
SAS PROC MIXED (SAS Institute, Cary, NC) was used
to analyze the data from the crossover trial. The Grizzles
model included treatment effect, carry-over effect, and
sequential effect as fixed effects and the subject effect as
a random effect. The model was fitted for seven different
Table 1 Baseline charateristics of participants (n = 37)
Characteristic Mean ± SD (or N/%)
Age (years) 61.2 ± 6.7
Male sex (n/%) 15 (40.5%)
Duration of diabetes (years) 10 ± 6
Hypertension 32 (86.5%)
Dyslipidemia 14 (37.8%)
Current smoker 13 (35.1%)
BMI (kg/m2) 26.2 ± 2.9
Waist circumference (cm) 92.5 ± 8.0
Systolic blood pressure (mmHg) 131.9 ± 11.8
Diastolic blood pressure (mmHg) 79.2 ± 11.4
Fasting glucose (mg/dL) 133.4 ± 27.1
HbA1c (%)* 7.1 ± 1.1
Fasting insulin (μIU/mL)* 11.6 ± 1.6
HOMA-IR* 3.8 ± 1.6
QUICKI 0.32 ± 0.02
Total cholesterol (mg/dL) 155.2 ± 25.2
Triglyceride (mg/dL)* 131.1 ± 1.7
HDL-C (mg/dL) 46.2 ± 9.9
LDL-C (mg/dL) 91.6 ± 21.2
hsCRP (mg/L)* 1.07 ± 2.65
Mean baPWV (cm/sec) 1591.4 ± 192.6
Adiponectin (ng/mL)* 8.86 ± 1.87
IL-6 (pg/mL)* 3.99 ± 2.94
TNF-α (ng/dL)* 6.36 ± 1.27
MCP-1 (ng/dL)* 590.2 ± 1.63
sVCAM-1 (ng/dL) 1224.4 ± 267.6
sICAM-1 (ng/dL)* 169.7 ± 1.29
HOMA-IR, homeostasis model assessment of insulin resistance, QUICKI
quantitative insulin sensitivity check index, hsCRP high sensitivity C-reactive
protein, baPWV brachial-ankle pulse wave velocity, IL-6 interleukin-6, TNF-α
tumor necrosis factor-alpha, MCP-1 monocyte chemotactic protein-1, sVCAM-1
soluble vascular cellular adhesion molecule-1, sICAM-1 soluble intercellular
adhesion molecule-1.
Data are presented as the mean ± SD. *Geometric mean ± SD.
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sVCAM-1, and sICAM-1). There were no significant
carry-over and sequential effects. Baseline characteristics
of study participants were comparable in both groups
and both phases. Primary outcome was change in arte-
rial stiffness measured by baPWV. Secondary outcome
was change in inflammatory markers. The sample size of
the study was determined on the basis of the estimation
for the primary outcome of baPWV from previous trials
[18,19]. Using a two-sided test for differences in inde-
pendent binomial proportions with an alpha level of
0.05, 36 patients would have to undergo randomization
for the study to have 80% power to detect a difference in
the baPWV between the two study arms. Therefore, atleast 48 patients were enrolled to account for an antici-
pated 25% loss in follow-up. The level of significance
was 0.05. All analyses were performed using SAS version
9.1.3 (SAS Institute).
Results
Forty five participants were randomly assigned to each
study arm. Two participants withdrew their consent for
participation before the first treatment phase and one
participant withdrew during the washout period. During
the first phase, two patients in the cilostazol arm with-
drew due to headache (n = 1) and dizziness (n = 1).
After completion of cilostazol treatment, three patients
withdrew due to headache (n = 2) and dizziness (n = 1).
As a result, 37 participants completed the full protocol
(Figure 1). Throughout the study period, the medications
were generally well tolerated by the 37 subjects. One
participant experienced mild headaches but completed
the study.
Table 1 summarizes the baseline characteristics of the
participants. The subjects comprised 15 males (40.5%)
and the mean age of the total participants was 61.2 ± 6.7
years. The mean duration of diabetes was 10 ± 6 years and
the mean BMI was 26.2 ± 2.9 kg/m2. The anthropometric
and biochemical data showed that, for most participants,
diabetes was generally well-controlled. The mean glycated
hemoglobin (HbA1c) level was 7.1%, mean systolic and
diastolic pressure was 131.9 and 79.2 mmHg, respectively,
mean total cholesterol was 155.2 mg/dL, and mean LDL
cholesterol was 91.6 mg/dL.
Table 2 shows changes from baseline to week 8 of an-
thropometric and metabolic parameters in both compari-
son groups. Baseline parameters were not significantly
different in both groups. After the 8-week treatment with
cilostazol or placebo, no anthropometric measure had
changed substantially. However, WC in the cilostazol
group significantly decreased from 92.6 to 91.4 cm
(P = 0.007). Lipid profiles including total cholesterol,
triglyceride, and HDL-C improved in both groups, but
none of the improvements was statistically significant.
Cilostazol treatment lowered mean baPWV from 1621.8 ±
229.8 to 1592.0 ± 249.3 cm/sec, but the decrease was not
statistically significant. Most of inflammatory markers
including adiponectin, IL-6, MCP-1, sVCAM-1, and
sICAM-1 showed tendency of improvement with
cilostazol. However, there was significant change only in
sVCAM-1 level (1288.7 ± 285.6 to 1168.2 ± 252.3 ng/dL,
P = 0.0003) and a modest change in serum adiponectin
level (9.17 ± 1.88 to 9.92 ± 1.93 ng/mL, P = 0.07). There
were no significant changes of outcomes in the placebo
group except IL-6 (4.13 ± 3.14 to 3.21 ± 3.34 pg/mL,
P = 0.02).
Comparing the effect of ciolstazol and placebo on the
outcomes, cilostazol significantly reduced sVCAM-1 level
Table 2 Changes from baseline to week 8 of anthropometric and metabolic parameters in cilostazol and placebo
group (n=37)
Placebo Cilostazol
Baseline Follow-up P-value Baseline Follow-up P-value
BMI (kg/m2) 26.2 ± 2.9 26.2 ± 2.9 0.29 26.2 ± 2.9 26.0 ± 2.9 0.12
Waist circumference (cm) 92.5 ± 8.0 92.1 ± 7.6 0.36 92.6 ± 8.0 91.4 ± 7.4 0.007
Systolic blood pressure (mmHg) 131.0 ± 10.8 131.1 ± 12.0 0.93 130.6 ± 11.2 129.6 ± 13.0 0.59
Diastolic blood pressure (mmHg) 79.6 ± 11.2 81.3 ± 10.3 0.35 79.4 ± 9.8 77.4 ± 9.3 0.20
Fasting glucose (mg/dL) 129.2 ± 22.2 129.6 ± 32.0 0.94 137.5 ± 41.2 140.2 ± 31.7 0.66
HbA1c (%)* 7.2 ± 1.2 7.1 ± 1.2 0.19 7.3 ± 1.2 7.2 ± 1.2 0.42
Fasting insulin (μIU/mL)* 11.0 ± 1.6 11.0 ± 1.6 0.99 11.1 ± 1.5 10.3 ± 1.5 0.21
HOMA-IR* 3.5 ± 1.6 3.6 ± 1.7 0.50 3.6 ± 1.6 3.5 ± 1.6 0.73
QUICKI 0.32 ± 0.02 0.32 ± 0.02 0.59 0.32 ± 0.02 0.32 ± 0.02 0.74
Total cholesterol (mg/dL) 156.7 ± 24.2 154.1 ± 23.6 0.49 157.9 ± 21.0 154.9 ± 23.0 0.39
Triglyceride (mg/dL)* 143.9 ± 1.7 140.7 ± 1.6 0.77 134.6 ± 1.6 121.9 ± 1.5 0.19
HDL-C (mg/dL) 43.0 ± 9.3 44.7 ± 13.1 0.37 47.1 ± 11.0 48.1 ± 10.9 0.41
LDL-C (mg/dL) 94.1 ± 21.6 90.3 ± 19.9 0.28 93.9 ± 19.9 88.9 ± 20.0 0.10
hsCRP (mg/L)* 1.09 ± 2.78 0.93 ± 3.28 0.39 0.90± 2.79 1.15 ± 2.24 0.09
Mean baPWV (cm/sec) 1597.9 ± 239.6 1606.7 ± 259.6 0.77 1621.8 ± 229.8 1592.0 ± 249.3 0.35
Adiponectin (ng/mL)* 8.44 ± 1.82 8.53 ± 1.95 0.72 9.17 ± 1.88 9.92 ± 1.93 0.07
IL-6 (pg/mL)* 4.13 ± 3.14 3.21 ± 3.34 0.02 4.33 ± 3.28 3.41 ± 2.48 0.74
TNF-α (ng/dL)* 6.66 ± 1.32 6.12 ± 1.36 0.07 6.42 ± 1.32 6.36 ± 1.37 0.87
MCP-1 (ng/dL)* 546.6 ± 1.43 577.5 ± 1.38 0.32 588.1 ± 1.57 570.4 ± 1.43 0.67
sVCAM-1 (ng/dL) 1227.6 ± 274.0 1225.1 ± 281.4 0.94 1288.7 ± 285.6 1168.2 ± 252.3 0.0003
sICAM-1 (ng/dL)* 158.4 ± 1.38 156.3 ± 1.39 0.70 155.2 ± 1.38 144.0 ± 1.35 0.10
HOMA-IR homeostasis model assessment of insulin resistance, QUICKI quantitative insulin sensitivity check index, hsCRP high sensitivity C-reactive protein, baPWV
brachial-ankle pulse wave velocity, IL-6 interleukin-6, TNF-α tumor necrosis factor-alpha, MCP-1 monocyte chemotactic protein-1, sVCAM-1 soluble vascular cellular
adhesion molecule-1, sICAM-1 soluble intercellular adhesion molecule-1.
Data are presented as the mean ± SD.
*Geometric mean ± SD, statistical significance was estimated after logarithmic transformation.
P-value were obtained using paired t-test based on change (follow-up–baseline) in each group.
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compared with placebo (Table 3). However, there were no
differences observed in baPWV, hsCRP, adiponectin, IL-6,
TNF-α, MCP-1, and sICAM-1 between the cilostazol and
placebo groups.
Discussion
To the best of our knowledge, this is the first randomized
controlled trial comparing the effect of cilostazol and pla-
cebo on arterial stiffness and biochemical markers related
to vascular inflammation including vascular cellular adhe-
sion molecules in diabetic patients without established
CVD. Cilostazol treatment for 8 weeks did not substan-
tially change PWV compared with placebo in patients with
type 2 diabetes and metabolic syndrome. However, there
was significant reduction of serum sVCAM-1 level, and
modest improvement of serum adiponectin level with
cilostazol treatment.
Arterial stiffness primarily represents elastic property
of arteries and has a role in the development of CVD.Various simple and noninvasive methods measuring
arterial stiffness have been suggested and PWV is the
most widely-used method in the clinical setting. Among
various methods of measurement of PWV, baPWV cor-
relates well with carotid-femoral PWV and aortic PWV
[20,21], and has been closely associated with incident
hypertension [22], insulin resistance [23], and coronary
atherosclerosis [24].
Initially, we hypothesized that cilostazol would im-
prove arterial stiffness. Cilostazol is a phosphodiesterase
3 inhibitor; this inhibition and associated increase in
cAMP in platelets and vascular smooth muscle cells
contributes to the antiplatelet and vasodilatory effects
of cilostazol [25]. In several clinical trials, cilostazol
treatment attenuated the increase of carotid IMT com-
pared with placebo group in type 2 diabetic patients
[13,26]. Recently, the Diabetic Atherosclerosis Preven-
tion by Cilostazol study found that cilostazol more po-
tently inhibited progression of carotid IMT in diabetic
patients, even compared with aspirin [12]. In addition,
Table 3 Effect of cilostazol vs. placebo on anthropometric and metabolic parameters
Mean difference 95% CI for the difference P-value
BMI (kg/m2) 0.29 −0.03 to 0.61 0.08
Waist circumference (cm) 0.88 −0.28 to 2.03 0.13
Systolic blood pressure (mmHg) 0.76 −4.95 to 6.47 0.79
Diastolic blood pressure (mmHg) 3.07 −1.75 to 7.90 0.21
Fasting glucose (mg/dL) −3.60 −17.04 to 9.84 0.59
HbA1c (%)* −0.01 −0.05 to 0.03 0.53
Fasting insulin (μIU/mL)* 0.07 −0.12 to 0.25 0.45
HOMA-IR* 0.06 −0.17 to 0.29 0.59
QUICKI −0.00 −0.01 to 0.01 0.70
Total cholesterol (mg/dL) −1.21 −11.46 to 9.05 0.81
Triglyceride (mg/dL)* 0.05 −0.15 to 0.26 0.61
HDL-C (mg/dL) 0.98 −3.54 to 5.51 0.66
LDL-C (mg/dL) −0.71 −9.65 to 8.24 0.87
hsCRP (mg/L)* −0.38 −0.84 to 0.09 0.11
Mean baPWV (cm/sec) 31.42 −55.67 to 118.50 0.47
Adiponectin (ng/mL)* −0.07 −0.17 to 0.03 0.16
IL-6 (pg/mL)* −0.18 −0.61 to 0.26 0.38
TNF-α (ng/dL)* −0.08 −0.22 to 0.06 0.27
MCP-1 (ng/dL)* 0.08 −0.11 to 0.27 0.41
sVCAM-1 (ng/dL) 105.18 10.65 to 199.71 0.03
sICAM-1 (ng/dL)* 0.06 −0.05 to 0.18 0.28
HOMA-IR homeostasis model assessment of insulin resistance, QUICKI, quantitative insulin sensitivity check index, hsCRP high sensitivity C-reactive protein, baPWV
brachial-ankle pulse wave velocity, IL-6 interleukin-6, TNF-α tumor necrosis factor-alpha, MCP-1 monocyte chemotactic protein-1, sVCAM-1 soluble vascular cellular
adhesion molecule-1, sICAM-1 soluble intercellular adhesion molecule-1.
Mean difference = placebo-cilostazol.
*Statistical significance was estimated after logarithmic transformation.
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with arteriosclerosis obliterans [27], and increased co-
ronary flow reserve in patients with coronary artery
disease [28].
The present results did not prove the efficacy of
cilostazol to improve the arterial stiffness. Although the
mean baPWV was slightly decreased with cilostazol and
increased with placebo, there was no significant difference
between the two groups. There are several possible expla-
nations for this result. First, the study period might not
have been long enough. Although there is no established
study period for which a clinical outcome becomes appa-
rent, the present study was a relatively short study period
compared with other studies involving cilostazol. Second,
most of the patients (31 of 37 subjects; 83.7%) had already
undergone treatment with angiotensin-converting enzyme
inhibitor or angiotensin II receptor blockade, and a con-
siderable number of participants already had taken statins
(14 of 37 subjects; 37.8%) because we wanted to investi-
gate the additional effect of cilostazol in a real clinical
setting. So, it is possible that further improvement with
cilostazol treatment might not be noted due to these drugs
that might already affect arterial stiffness. Indeed, in asubgroup analysis, except for the subjects using statins,
the effect of cilostazol was more prominent, although not
statistically significant (data not shown).
The antiatherogenic and antiimflammatory effects of
cilostazol may be come from cAMP-mediated increase in
lipoprotein lipase and inhibition of cytokine production.
An in vivo study reported cilostazol-associated increase in
cardiac lipoprotein lipase in streptozotocin-induced dia-
betic rats [11]. Cilostazol also significantly reduced the in-
creased TNF-α production induced by lipopolysaccharide
in human umbilical vein endothelial cells [29]. In addition,
recent in vitro studies found that cilostazol reduced the
expression of VCAM-1 and MCP-1 and activate the
production of nitric oxide [30,31]. In clinical studies,
cilostazol treatment decreased P2Y12 reactivity index as a
marker of platelet function [32], also decreased hsCRP
and soluble CD40 ligand levels, and increased adiponectin
level in diabetic patients with peripheral arterial occlusion
disease [14].
This study is the first clinical study that proved the
beneficial effect of cilostazol on sVCAM-1 level, and
adds to the evidence to the clinically-apparent anti-
inflammatory role of cilostazol. VCAM-1 and ICAM-1
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tion as endothelial ligands for integrins. Previous studies
suggested that VCAM-1 has a role in the recruitment of
leukocytes in early atherosclerotic lesions via interaction
with VLA-4 integrins on monocytes and lymphocytes
[33,34]. Higher levels of soluble VCAM-1 have been docu-
mented in subjects with type 2 diabetes [35], metabolic
syndrome [36], and atherosclerosis [37], and have been
associated with increased CVD mortality [4]. A clinical
study showed reduced sVCAM-1 levels in obese women
after weight loss over 1-year [38]. Presently, cilostazol
modestly decreased IL-6, MCP-1, and sICAM-1 levels in
addition to sVCAM-1 with short term treatment. These
findings indicate that cilostazol might have an anti-
inflammatory role in the early phase of atherosclerosis
progression, and it is conceivable that cilostazol could
improve other inflammatory markers with a longer treat-
ment period.
Several limitations of our study must be acknow-
ledged. First, this study was confined to type 2 diabetic
patients with metabolic syndrome, and results from this
study should not be extrapolated to other patient popu-
lations. Secondly, our study was performed using a small
number of patients over a short period of time. Whether
the observed effect of cilostazol on serum sVCAM-1
level in these patients translates into cardiovascular out-
comes should be evaluated by a long-term, large scale,
randomized, multicenter study. Third, we did not meas-
ure other markers related to platelet function or platelet
activation such as soluble CD40 ligand, which might be
helpful for assessment and interpretation of the effects
of cilostazol on vascular inflammation.Conclusion
Despite of its potential favorable effects on arterial stiff-
ness, treatment with cilostazol for 8 weeks did not
improve the mean baPWV compared with placebo treat-
ment in diabetic patients with metabolic syndrome but
not having established CVD. However, this short term
treatment was associated with significant reduction of
sVCAM-1 level, and modest improvement of adiponectin
level. We could not exclude the possibility that cilostazol
would improve the vascular outcomes over a longer time.
Further studies are needed to elucidate the distinct effects
of cilostazol in type 2 diabetes, especially with long-term
treatment.
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